Associated Papers
Molecular insights into CYP19A1 mutations and their role in estrogen production.
Lee YB et al.
Archives of Biochemistry and Biophysics, 2025
CYP19A1 mediates severe SARS-CoV-2 disease outcome in males.
Stanelle-Bertram S et al.
Cell Reports. Medicine, 2023
Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine.
Zhou Y et al.
Science Advances, 2021
In silico analysis of nsSNPs in CYP19A1 gene affecting breast cancer associated aromatase enzyme.
Pavithran H et al.
Journal of Genetics, 2021
Adenomyosis: genetics of estrogen metabolism.
Artymuk N et al.
Hormone Molecular Biology and Clinical Investigation, 2019
Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti-aromatase activity assay examining exemestane and its derivatives.
Peterson A et al.
Pharmacology Research & Perspectives, 2017
NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of sex development.
Baetens D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors.
Hoffmann MJ et al.
Bladder Cancer (amsterdam, Netherlands), 2016
Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy.
Blackburn HL et al.
Cancer Causes & Control : Ccc, 2015
A non-synonymous coding change in the CYP19A1 gene Arg264Cys (rs700519) does not affect circulating estradiol, bone structure or fracture.
Wang JZ et al.
Bmc Medical Genetics, 2011
Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population.
Lee SJ et al.
Journal of Human Genetics, 2010
Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists.
Sigurdson AJ et al.
Breast Cancer Research and Treatment, 2009
CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.
Travis RC et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2009
In vitro kinetic properties of the Thr201Met variant of human aromatase gene CYP19A1: functional responses to substrate and product inhibition and enzyme inhibitors.
Payne EJ et al.
The Journal of Clinical Endocrinology and Metabolism, 2009
A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.
Wang LL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
Vaarala MH et al.
International Journal of Cancer, 2008
A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.
Olson JE et al.
Breast Cancer Research and Treatment, 2007
Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
Haiman CA et al.
Cancer Research, 2007
Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.
Mononen N et al.
Cancer Research, 2006
Human aromatase: gene resequencing and functional genomics.
Ma CX et al.
Cancer Research, 2005